查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1867191

可待因市场依产品类型、剂型、用途、通路和最终用户划分－2025-2032年全球预测

Codeine Market by Product Type, Form, Application, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，可待因市场规模将成长至 59.8 亿美元，复合年增长率为 4.79%。

关键市场统计数据
基准年 2024 41.1亿美元
预计年份：2025年 43.1亿美元
预测年份 2032 59.8亿美元
复合年增长率 (%) 4.79%

全面概述可待因疗法，包括其临床作用、监管复杂性、安全问题以及医疗保健领域相关人员不断变化的期望

可待因在现代治疗实务中占有复杂而重要的地位，它既是一种长期使用的镇痛和镇咳药物，也是监管机构和公共卫生政策的焦点。临床上，可待因的药理特性及其在组合药物中的应用使其在包括疼痛管理和止咳在内的多种适应症中保持着重要作用。然而，其代谢特性和患者反应的个体差异意味着需要谨慎用药。近年来，卫生部门和处方医生越来越重视风险控制、患者选择以及适合不同年龄层的製剂，尤其是在儿童和老年人群中。

深入分析受监管加强、治疗替代、供应韧性以及处方趋势等因素影响，正在重塑可待因市场格局的关键变化。

可待因市场正经历多重变革，重塑临床实务、供应链结构和监管因应措施。多个司法管辖区加强监管，提高了处方、标籤和上市后监测的标准，促使生产商和临床医生优先考虑风险管理措施和循证药物管理方案。同时，治疗替代疗法和针对特定适应症的非阿片类替代药物的推广，正在改变处方趋势，并促使人们更加关注多模式疼痛管理方案以及在临床适宜的情况下使用非阿片类止咳药。

评估2025年美国关税对可待因供应链、原料药采购成本、临床应用和生产的累积影响

2025年美国关税政策对全球可待因生态系统累积，促使企业调整筹资策略，揭露原料药采购成本差异，并重新评估库存和製造地。影响关键中间体和原料药进口的关税变化，促使製造商考虑近岸外包和供应商多元化，以此保障供应连续性，同时也提升了垂直整合生产能力的战略价值。为此，采购部门正在扩展供应商资格认证流程，并加强对供应商绩效的监控，以保护临床用品免受暂时性贸易摩擦的影响。

细分市场分析揭示了不同产品类型、配方选择、临床应用、分销管道和终端用户环境的需求模式。

细分市场分析揭示了不同的需求驱动因素和临床要求如何转化为差异化的产品开发和分销策略。按产品类型划分，盐酸可待因、磷酸可待因、硫酸可待因和復方製剂之间的差异决定了化学品采购途径、製剂相容性和监管文件配置。复方製剂通常需要额外的动态和安全性验证。按剂型划分，注射剂、糖浆和片剂之间的动态影响着临床应用案例和供应链选择。注射剂的需求受肌肉注射和静脉注射两个细分市场的影响，这两个细分市场对无菌性和低温运输的要求不同。糖浆的选择取决于含糖或无糖选项，这与患者群体和标籤要求有关。同时，片剂剂型必须平衡缓释性和速释特性，以满足疼痛管理的需求。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 对非处方可待因销售限制的收紧影响了市场进入和消费行为。
  • 新兴市场对含低剂量可待因的止咳药需求不断成长
  • 公共卫生和政策倡议推动了向防滥用可待因製剂的过渡。
  • 开发一种数位处方监测工具，以防止可待因的滥用和转移。
  • 全球供应链中断对可待因原料供应和价格的影响
  • 受鸦片类药物危机影响而进行的医疗改革可能会导致可待因处方行为的审查增加。
  • 减少可待因在轻度疼痛管理的偏好偏好非鸦片类止痛药
  • 非专利药可待因产品系列的扩大加剧了生产商之间的价格竞争。
  • 网路药局和灰色市场通路的兴起，助长了全球范围内不受监管的可待因分销。
  • 创新固定剂量可待因复方製剂疗法，以因应病患依从性挑战

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按产品类型分類的可待因市场

  • 盐酸可待因
  • 磷酸可待因
  • 硫酸可待因
  • 组合药物

9. 按剂型分類的可待因市场

  • 注射
    • 肌肉内注射
    • 静脉注射
  • 糖浆
    • 糖度
    • 无醣
  • 药片
    • 缓释性
    • 立即生效

第十章 按应用分類的可待因市场

  • 止咳药
    • 成人配方
    • 儿科配方
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛

第十一章 按分销管道分類的可待因市场

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 依最终用户分類的可待因市场

  • 诊所
  • 居家医疗
  • 医院

13. 各地区可待因市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的可待因市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国可待因市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Johnson & Johnson
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Sandoz International GmbH
    • GlaxoSmithKline plc
    • Aurobindo Pharma Limited
    • Cipla Limited
    • Dr. Reddy's Laboratories Limited
    • Sun Pharmaceutical Industries Limited
Product Code: MRR-99555D550530

The Codeine Market is projected to grow by USD 5.98 billion at a CAGR of 4.79% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.11 billion
Estimated Year [2025] USD 4.31 billion
Forecast Year [2032] USD 5.98 billion
CAGR (%) 4.79%

Comprehensive overview of codeine therapeutics, clinical roles, regulatory complexities, safety concerns, and evolving stakeholder expectations in healthcare

Codeine occupies a complex and consequential position within contemporary therapeutic practice, serving as both a long-established analgesic and antitussive agent and a focal point for regulatory scrutiny and public health policy. Clinically, codeine's pharmacologic profile and its inclusion in combination products have sustained its role across a range of pain management and cough suppression indications, while its metabolism and potential for variable patient response have driven careful stewardship in prescribing. Over recent years, health authorities and prescribers have intensified emphasis on risk mitigation, patient selection, and age-appropriate formulations, particularly where pediatric and elderly populations are concerned.

As a result, manufacturers, clinicians, and distributors operate in an environment where supply continuity, formulation innovation, and compliance with divergent national regulations converge. This environment demands a layered understanding of product variants, permissible formulations, and the interplay between clinical utility and safety obligations. Transitional technologies such as tele-prescribing, combined with evolving pharmacovigilance expectations, are changing how codeine products are accessed and monitored. Consequently, stakeholders must balance therapeutic access with robust mitigation of misuse and diversion risks while maintaining operational resilience across manufacturing and distribution channels.

In-depth review of major shifts reshaping the codeine landscape driven by regulatory tightening, therapeutic substitution, supply resilience and prescribing

The landscape for codeine is undergoing several transformative shifts that are redefining clinical practice, supply chain architecture, and regulatory engagement. Regulatory tightening in multiple jurisdictions has elevated the standards for prescribing, labeling, and post-market surveillance, prompting manufacturers and clinicians to prioritize risk management measures and evidence-based stewardship programs. Concurrently, therapeutic substitution and the expansion of non-opioid alternatives for specific indications have altered prescribing trajectories, encouraging greater emphasis on multimodal pain management pathways and non-opioid antitussives where clinically appropriate.

Supply chain resilience has become a strategic imperative as raw material controls, geopolitical tensions, and logistic bottlenecks expose vulnerabilities in active pharmaceutical ingredient sourcing and finished product distribution. At the same time, innovation in formulations-ranging from sugar-free syrups to extended-release tablets and combination products-reflects both patient-centric demands and regulatory accommodation for safer dosing. Digital tools for prescribing, adverse-event monitoring, and adherence support are gaining traction, aligning clinical decision-making with real-world safety data. Together, these shifts are creating a healthcare ecosystem in which manufacturers, payers, and providers must coordinate to ensure therapeutic access while meeting heightened expectations for safety, transparency, and supply continuity.

Evaluation of cumulative effects from United States tariff actions in 2025 on codeine supply chains, API sourcing costs, clinical access, and manufacturing

United States tariff actions implemented in 2025 have exerted a cumulative effect on the global codeine ecosystem by redirecting sourcing strategies, exposing cost differentials in active pharmaceutical ingredient procurement, and prompting reassessments of inventory and manufacturing footprints. Tariff changes affecting key intermediates and finished product imports have encouraged manufacturers to evaluate nearshoring and supplier diversification as mechanisms to protect supply continuity, while also increasing the strategic value of vertically integrated production capabilities. In response, procurement teams have expanded supplier qualification processes and intensified supplier performance monitoring to insulate clinical supply from episodic trade friction.

Clinicians and health systems have experienced indirect consequences through procurement cycles and formulary reviews, leading to an increased preference for products with stable supply chains and transparent provenance. Pharmaceutical manufacturers have accelerated conversations on domestic production capacity, contract manufacturing partnerships, and API substitution where scientific and regulatory frameworks permit. Regulatory authorities and trade policymakers have, in some cases, instituted exemptions or expedited review pathways for essential medicines to preserve clinical access, and private-sector actors have adopted hedging strategies in inventory management to mitigate near-term disruptions. The net effect is a recalibration of operational priorities where trade policy, clinical continuity, and production agility intersect.

Segmentation insights revealing demand patterns across product types, formulation options, clinical applications, distribution channels and end-user settings

Segmentation analysis reveals how heterogeneous demand drivers and clinical requirements translate into differentiated product development and distribution strategies. Based on product type, distinctions among Codeine Hydrochloride, Codeine Phosphate, Codeine Sulfate, and Combination Products determine chemical sourcing pathways, formulation compatibility, and regulatory dossier composition, with combination products often requiring additional pharmacodynamic and safety demonstration. Based on form, the dynamics between Injection, Syrup, and Tablet formats influence clinical use cases and supply chain choices; Injection demand is shaped by intramuscular and intravenous subsegments that impose distinct sterility and cold-chain requirements, Syrup offerings are influenced by sugar based and sugar free choices tied to patient populations and labeling expectations, while Tablet formats must balance extended release and immediate release profiles to meet analgesic regimens.

Based on application, differentiation between Cough Suppression and Pain Management carries implications for age segmentation and dosing strategies; cough suppression pathways further divide into adult formulations and pediatric formulations that require separate clinical and regulatory attention, and pain management splits into acute pain and chronic pain pathways that demand tailored benefit-risk assessments. Based on distribution channel, the roles of Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy affect inventory management, prescription validation, and patient counseling practices. Finally, based on end user, clinics, home care, and hospitals each present unique procurement behaviors and clinical governance frameworks that must be addressed through targeted commercial and clinical strategies to ensure appropriate access and oversight.

Regional comparative insights exposing regulatory variation, clinical access challenges, supply chain fragility, and demand trends guiding strategic priorities

Regional dynamics exert a persistent influence on how codeine products are regulated, supplied, and used in clinical practice, and variations by geography shape both short-term responses and long-term strategies. In the Americas, regulatory frameworks and healthcare delivery systems create a mix of centralized procurement and diverse prescribing practices, producing a landscape in which supplier reliability and distribution accountability are highly valued. In Europe, Middle East & Africa, fragmentation across regulatory regimes and heterogenous reimbursement environments combine with strong pharmacovigilance expectations to require regionally nuanced regulatory strategies and rigorous post-market monitoring. In Asia-Pacific, rapid expansion of healthcare infrastructure and varying degrees of local manufacturing capacity have produced both opportunities for domestic production and the need to harmonize quality standards to enable cross-border supply.

Across these regions, supply chain resilience, regulatory alignment, and clinical stewardship priorities diverge in emphasis but converge on shared objectives: preserving safe therapeutic access, ensuring traceable supply chains, and mitigating misuse. Strategic decisions regarding manufacturing footprint, regulatory submissions, and distribution partnerships must therefore be informed by region-specific constraints and enablers. Effective regional strategies incorporate local regulatory engagement, tailored clinical education initiatives, and commercially feasible logistics arrangements, enabling stakeholders to reconcile global product strategies with the operational realities of each geography.

Company insights into innovation strategies, portfolio diversification, manufacturing adaptability and partnerships shaping the competitive codeine landscape

Company-level dynamics in the codeine landscape reflect a balance between innovation, operational flexibility, and compliance with tightening regulatory requirements. Leading manufacturers and generic producers have prioritized portfolio diversification and formulation innovation to retain clinical relevance while addressing safety concerns and patient preferences. Strategic investments in sugar free syrup formulations, pediatric-appropriate dosing forms, and extended-release tablets demonstrate how product design can mitigate certain clinical risks and improve adherence across specific patient cohorts.

At the same time, manufacturing adaptability and supply chain transparency have emerged as core competitive differentiators. Companies that have invested in multi-sourced APIs, GMP-compliant facilities, and validated contract manufacturing partnerships are better positioned to navigate procurement disruptions and policy shifts. Commercial strategies increasingly emphasize collaborative relationships with healthcare systems, pharmacovigilance data sharing, and targeted clinical education to support appropriate use. Partnerships with contract research and manufacturing organizations enable faster scale-up and flexibility, while proprietary formulation know-how and robust quality systems sustain regulatory readiness and market access.

High-impact, pragmatic recommendations for industry leaders to balance patient access, regulatory compliance, supply security, and responsible opioid stewardship

To sustain therapeutic access while meeting heightened safety expectations and supply uncertainties, industry leaders should pursue a set of pragmatic, high-impact actions. Strengthening supplier networks and qualifying alternative API sources will reduce single-source risk and create room for agile manufacturing responses when trade policies or logistics issues arise. Concurrently, investing in formulation diversification-such as developing sugar free syrups, pediatric-friendly doses, and controlled-release tablets-aligns product offerings with evolving clinical guidance and patient needs. These investments should be coupled with enhanced pharmacovigilance systems and active collaboration with regulators to ensure labeling and usage guidance reflect best available evidence.

Commercially, organizations should prioritize transparent communication with healthcare providers and payers to build confidence in product quality and continuity. This includes targeted education programs on responsible prescribing, adverse-event reporting, and appropriate substitution where applicable. Operationally, leaders should consider capacity-building in contract manufacturing relationships and regional production hubs to buffer against external shocks. Finally, governance mechanisms that integrate compliance, clinical stewardship, and supply planning into executive decision-making will support balanced outcomes that preserve patient access while limiting misuse and diversion.

Methodology combining primary stakeholder interviews, regulatory review, clinical evidence synthesis, and multi-source validation to deliver actionable insights

The research underlying this analysis combines primary stakeholder engagement, regulatory review, clinical evidence synthesis, and rigorous multi-source validation to produce actionable findings. Primary inputs included structured interviews with clinicians, regulatory specialists, supply chain managers, and commercial leaders to capture operational realities and emergent practice patterns. Regulatory documents, clinical guidelines, and peer-reviewed literature were systematically reviewed to ground interpretation in current standards of care and safety expectations. Synthesis of these inputs enabled triangulation of clinical trends, formulation preferences, and distribution behaviors.

Data quality controls included cross-validation of interview findings against published guidance and manufacturing standards, and iterative expert feedback to refine interpretations and recommendations. Segmentation and regional analyses were constructed to align product, form, application, distribution, and end-user perspectives with geographic regulatory environments. The methodology prioritized transparency in assumptions and traceability of sources, enabling readers to follow the evidentiary basis for conclusions and to request tailored analyses aligned with specific commercial or operational questions.

Conclusion synthesizing clinical, regulatory, supply chain, and commercial imperatives that will shape near-term therapeutic use and stewardship priorities

In summary, the therapeutic and commercial trajectory for codeine products is shaped by intersecting forces: intensified regulatory scrutiny, evolving clinical alternatives, persistent supply chain vulnerabilities, and the need for prudent stewardship to minimize harm. These forces require integrated strategies that align product design, supply architecture, and clinician engagement to maintain safe access while reducing potential for misuse. As regulatory frameworks continue to evolve and trade dynamics exert influence on sourcing and pricing behavior, stakeholders who proactively adapt their manufacturing, procurement, and clinical support models will be best positioned to sustain reliable supply and clinical relevance.

Looking ahead, effective responses will combine investment in formulation and manufacturing flexibility with robust pharmacovigilance and targeted education for prescribers and patients. Embedding these approaches within corporate governance and regional operational plans will enable organizations to reconcile public health obligations with commercial viability. The imperative is clear: a coordinated, evidence-based approach that safeguards patient access while strengthening the resilience and accountability of the codeine supply chain will define success in the near term.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing regulatory restrictions on over-the-counter codeine sales impacting market access and consumer behavior
  • 5.2. Emerging market demand growth for low-dose codeine combination products in cough remedies
  • 5.3. Shift towards abuse-deterrent codeine formulations driven by public health and policy initiatives
  • 5.4. Development of digital prescription monitoring tools to prevent codeine misuse and diversion
  • 5.5. Impact of global supply chain disruptions on codeine raw material availability and pricing
  • 5.6. Growing scrutiny on codeine prescribing practices following opioid epidemic-driven healthcare reforms
  • 5.7. Consumer preference shift towards non-opioid analgesics reducing codeine usage in mild pain management
  • 5.8. Expansion of generic codeine product portfolios intensifying price competition among manufacturers
  • 5.9. Rise of online pharmacies and gray market channels facilitating unregulated codeine distribution worldwide
  • 5.10. Innovations in fixed-dose codeine combination therapies addressing patient adherence challenges

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Codeine Market, by Product Type

  • 8.1. Codeine Hydrochloride
  • 8.2. Codeine Phosphate
  • 8.3. Codeine Sulfate
  • 8.4. Combination Products

9. Codeine Market, by Form

  • 9.1. Injection
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
  • 9.2. Syrup
    • 9.2.1. Sugar Based
    • 9.2.2. Sugar Free
  • 9.3. Tablet
    • 9.3.1. Extended Release
    • 9.3.2. Immediate Release

10. Codeine Market, by Application

  • 10.1. Cough Suppression
    • 10.1.1. Adult Formulations
    • 10.1.2. Pediatric Formulations
  • 10.2. Pain Management
    • 10.2.1. Acute Pain
    • 10.2.2. Chronic Pain

11. Codeine Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Codeine Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Codeine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Codeine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Codeine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Johnson & Johnson
    • 16.3.2. Sanofi S.A.
    • 16.3.3. Teva Pharmaceutical Industries Ltd.
    • 16.3.4. Viatris Inc.
    • 16.3.5. Sandoz International GmbH
    • 16.3.6. GlaxoSmithKline plc
    • 16.3.7. Aurobindo Pharma Limited
    • 16.3.8. Cipla Limited
    • 16.3.9. Dr. Reddy's Laboratories Limited
    • 16.3.10. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CODEINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CODEINE MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CODEINE MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CODEINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CODEINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CODEINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CODEINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CODEINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CODEINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CODEINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CODEINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CODEINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CODEINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CODEINE MARKET SIZE, BY CODEINE HYDROCHLORIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CODEINE MARKET SIZE, BY CODEINE PHOSPHATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CODEINE MARKET SIZE, BY CODEINE SULFATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CODEINE MARKET SIZE, BY COMBINATION PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CODEINE MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CODEINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CODEINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CODEINE MARKET SIZE, BY SYRUP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CODEINE MARKET SIZE, BY SUGAR BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CODEINE MARKET SIZE, BY SUGAR FREE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CODEINE MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CODEINE MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CODEINE MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CODEINE MARKET SIZE, BY COUGH SUPPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CODEINE MARKET SIZE, BY ADULT FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CODEINE MARKET SIZE, BY PEDIATRIC FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CODEINE MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CODEINE MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CODEINE MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CODEINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CODEINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CODEINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CODEINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CODEINE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CODEINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CODEINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CODEINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CODEINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CODEINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 338. ASIA-PACIFIC CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 339. ASIA-PACIFIC CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 340. ASIA-PACIFIC CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 341. ASIA-PACIFIC CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 342. ASIA-PACIFIC CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 343. ASIA-PACIFIC CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 344. ASIA-PACIFIC CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 345. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 346. ASIA-PACIFIC CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 347. ASIA-PACIFIC CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 348. ASIA-PACIFIC CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 349. ASIA-PACIFIC CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 350. ASIA-PACIFIC CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 351. ASIA-PACIFIC CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 352. ASIA-PACIFIC CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 353. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 354. GLOBAL CODEINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 355. ASEAN CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 356. ASEAN CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 357. ASEAN CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 358. ASEAN CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 359. ASEAN CODEINE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 360. ASEAN CODEINE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 361. ASEAN CODEINE MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
  • TABLE 362. ASEAN CODEINE MARKET SIZE, BY INJECTION, 2025-2032 (USD MILLION)
  • TABLE 363. ASEAN CODEINE MARKET SIZE, BY SYRUP, 2018-2024 (USD MILLION)
  • TABLE 364. ASEAN CODEINE MARKET SIZE, BY SYRUP, 2025-2032 (USD MILLION)
  • TABLE 365. ASEAN CODEINE MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 366. ASEAN CODEINE MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 367. ASEAN CODEINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 368. ASEAN CODEINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 369. ASEAN CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2018-2024 (USD MILLION)
  • TABLE 370. ASEAN CODEINE MARKET SIZE, BY COUGH SUPPRESSION, 2025-2032 (USD MILLION)
  • TABLE 371. ASEAN CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 372. ASEAN CODEINE MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 373. ASEAN CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 374. ASEAN CODEINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 375. ASEAN CODEINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 376. ASEAN CODEINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 377. GCC CODEINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 378. GCC CODEINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 379. GCC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 380. GCC CODEINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 381. GCC CODEINE